Meta-Analysis
Copyright ©The Author(s) 2022.
World J Clin Cases. Jun 26, 2022; 10(18): 6091-6104
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6091
Figure 4
Figure 4 Forest plot comparing infliximab and adalimumab for the incidence of secondary loss of response. ADA: Adalimumab; IFX: Infliximab; CI: Confidence interval.